Does ‘nature’s Ozempic’ really work? Trendy GLP-1 supplements are designed to supercharge weight loss for a fraction of the price
Why fork over thousands of dollars a month for prescription weight loss jabs when store-bought supplements claim to have the ...
Barchart on MSN4h
Snag This Biotech Stock Before November, Here's Why
As retail investors flock to Viking Therapeutics, the biotech firm is also catching the eye of billionaire fund managers like ...
Viking Therapeutics, Inc. (VKTX): Biotech Breakthrough or Short Sellers’ Target?
We recently published a list of 10 Worst Booming Stocks to Buy According to Short Sellers. In this article, we are going to ...
Altimmune: Updated Data Supports Pemvidutide's 'Market Disruptor' Prospects
Pemvidutide's potential in obesity and MASH, combined with lean mass preservation, could make it a market leader in the ...
Eli Lilly: Sticking With A $1000 Target Ahead Of Q3 Earnings, New Trading Range
Eli Lilly surged 58% in 2024, driven by weight-loss drugs and strong earnings. The technical chart shows consolidation. See ...
What Experts Think About Lemme's New GLP-1 Supplement
The new Lemme GLP-1 Daily Capsules are being called an "Ozempic alternative." But do they really work — and if so, at what ...
Becker's Spine Review23h
GLP-1s raise risk of infection in ankle procedures: Study
Patients prescribed glucagon-like peptide-1 agonists, including Ozepmic and Wegovy, have a significantly higher postoperative infection rate following ankle-fusion procedures, according to a Sept. 20 ...